Moderna To Focus On Messenger RNA Approaches To Recreate Therapeutic Proteins
This article was originally published in The Pink Sheet Daily
The latest biotech to emerge from Flagship Ventures’ incubator is Moderna, which plans to focus on rare diseases in-house while out-licensing its technology for larger indications.
You may also be interested in...
The mRNA-focused company has inked a deal with Alexion for its work in rare diseases, promising plenty of cash in its future and further validation of its technology.
Start-ups raised a total of $670.3 million across all industries in Q4 2012, just $11.6 million less than in Q3, and 90% of that money went to biopharma companies. Several start-up companies inked deals with Big Pharmas, and there were three acquisitions – two in biopharma and one in the device sector.
Only a few biopharmaceutical start-ups have formed in the emerging microbiome space, but VC firm Flagship says its homegrown Seres Health, still somewhat stealthy, is developing a new category of drugs that aim to rebalance microbiome populations causing disease.